Biological Valley Performance Express: Expected loss of 55.8469 million yuan in 2025.

BioValley released its performance report on February 12th, achieving operating income of 433 million yuan in 2025, a year-on-year decrease of 16.12%; the net profit attributable to shareholders of the listed company was -55.8469 million yuan. During the reporting period, the increase in sales volume of the company's core central procurement products, Dengzhan Shengmai Capsule and Dengzhan Xixin Injection, was affected by intensified competition in the medical and health industry, as well as industry policy adjustments, but the hanging net prices in various sales regions showed varying degrees of decline; the sales volume of the company's core products increased significantly year-on-year, driving up operating costs accordingly, and the product gross margin decreased compared to the previous period.